Medicine and Dentistry
Malignant Neoplasm
100%
Immune Checkpoint Inhibitor
98%
Acute Kidney Injury
56%
Transplantation
47%
Cancer
47%
Nephrotoxicity
40%
Liver Transplantation
40%
Nephrology
37%
Cholangiocarcinoma
36%
Oncology
35%
Immunotherapy
33%
Immunity
32%
Hematopoietic Stem Cell Transplantation
27%
Interstitial Nephritis
25%
Diseases
24%
Kidney Function
24%
Overall Survival
23%
Systemic Therapy
22%
Kidney Injury
19%
Immune-Related Adverse Events
18%
Stem Cell Transplant
18%
Neoadjuvant Therapy
17%
Gemcitabine
17%
Rituximab
17%
Hepatocellular Carcinoma
16%
BK Virus
16%
Cisplatin
15%
Kidney Graft
15%
Graft Versus Host Reaction
15%
Biopsy Technique
14%
Pancreas Cancer
14%
Hemorrhagic Cystitis
14%
Tolfenamic Acid
14%
Myeloma
14%
Vasculitis
14%
Chronic Kidney Disease
14%
Melanoma
14%
Glomerulonephritis
13%
Metastatic Carcinoma
13%
Allogeneic Hematopoietic Stem Cell Transplantation
13%
Cancer Treatment
12%
Nephropathy
12%
Immunosuppressive Treatment
12%
Thrombotic Thrombocytopenic Purpura
12%
Stem Cell Therapy
12%
Creatinine
11%
Nephritic Syndrome
11%
Graft Rejection
11%
Urinary Tract
11%
Acute Renal Failure
11%
Keyphrases
Immune Checkpoint Inhibitors
92%
Checkpoint Inhibitors
38%
Liver Transplantation
38%
Cholangiocarcinoma
36%
Tolfenamic Acid
36%
Acute Kidney Injury
36%
Cancer Patients
34%
In Cancer
34%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
33%
Transplant Oncology
25%
Orthotopic Liver Transplantation
22%
Renal Toxicity
22%
Hospitalized Cancer Patients
22%
Malignancy
21%
Immune-related Adverse Events
20%
Overall Survival
19%
Neoadjuvant Therapy
17%
Gemcitabine
17%
Specificity Protein 1
17%
Hepatocellular Carcinoma
16%
Pretransplant
16%
Cancer Treatment
16%
Cisplatin
15%
Improved Survival
15%
Kidney
14%
Multiple Myeloma
14%
Systemic Treatment
14%
C-Met
14%
Surgical Options
14%
Cancer Cell Growth
14%
Hemorrhagic Cystitis
14%
Nephrology
14%
Stem Cell Transplantation
14%
Immune Checkpoint
14%
Onconephrology
14%
Hematopoietic Stem Cell Transplantation
14%
Melanoma
13%
Transplant Patients
13%
Graft-versus-host Disease (GvHD)
12%
Kidney Function
11%
Kidney Injury
11%
Improved Outcomes
11%
Cancer Care
11%
Targeted Therapy
11%
American Society
11%
Nephrotoxicity
11%
Peri
10%
Chronic Kidney Disease
10%
IrAE
9%
Tumor Growth
9%
Pharmacology, Toxicology and Pharmaceutical Science
Malignant Neoplasm
66%
Immune Checkpoint Inhibitor
62%
Tolfenamic Acid
51%
Acute Kidney Failure
23%
Nephrotoxicity
22%
Immunotherapy
21%
Neoplasm
16%
Cancer Growth
16%
Pancreas Cancer
16%
Carcinogenesis
15%
Tumor Growth
15%
Adverse Event
14%
Multiple Myeloma
14%
Systemic Treatment
14%
Cell Nucleus Receptor
14%
Bile Duct Carcinoma
14%
Colon Carcinoma
14%
Rituximab
14%
Interstitial Nephritis
13%
Anticarcinogen
13%
Overall Survival
11%
Autoimmune Disease
11%
Esophagus Cancer
9%
Gemcitabine
9%
Clinical Trial
9%
Glomerulonephritis
9%
Non-Steroidal Anti-Inflammatory Drug
9%
Cisplatin
8%
Graft Versus Host Reaction
8%
Progression Free Survival
8%
Side Effect
8%
Clinical Feature
8%
Diseases
8%
Chronic Kidney Failure
8%
Programmed Death 1 Receptor
7%
Lung Cancer
7%
Mammalian Target of Rapamycin
7%
Cyclophosphamide
7%
Melanoma
7%
microRNA
7%
Programmed Death 1 Ligand 1
7%
2,5-Dimethoxy-4-iodoamphetamine
7%
Transcriptome
7%
Protein P53
7%
Pancreas Adenocarcinoma
7%
Cancer Inhibition
7%
Calcium Ion
7%
Polyposis
7%
Infliximab
7%
Metformin
7%